The use of cytotoxic agents for the management of advanced breast cancer has shown a considerable increase over the past ten years. The great expectations that so many workers had in the early days of the new cytotoxic agents may have been disappointed but their use in producing worth-while regression or stasis of growth is acknowledged.
A considerable amount of literature now exists reporting objective responses in advanced breast cancer produced by the drug cyclophosphamide which has now been in use since 1959. Over the past fiveyears we have treated 133 cases of advanced breast cancer which are suitable for assessment. This study is retrospective and is presented with all the requisite apologies and cautions. One hundred and two cases within this series were reported two years ago (Kunkler et al. 1967) ; the inclusion of a further 30 cases has allowed some improvement in our system of analysis and mainly substantiates our previous findings.
Nature of the Survey
The patients included in this series were mainly from the Cardiff Breast Clinic group and had often received previous ablative endocrine treatment. The selection of patients for treatment will be seen to favour those with extensive regional disease as opposed to widespread distant metal Present address: Cookridge Hospital. Leeds 16 2Present address: National Computing Centre, Quay House, Quay Street, Manchester 3 stases. Our data recorded the following information whenever possible: (1) Date of birth and date of first symptom. (2) Interval between first symptom and treatment, and from menopause where indicated. (3) The cancer-free interval.
(4) Interval from first recurrence to cyclophosphamide. (5) Interval of objective response to cyclophosphamide. (6) Details of all other treatment including surgery, radiotherapy and endocrine procedures, both simple or ablative. (7) Details of intravenous and oral cyclophosphamide for each patient, with full blood counts being done regularly throughout treatment.
Toxic effects, including alopecia, urinary and digestive symptoms, or purpura, were noted. Clinical response to treatment was recorded as objective, doubtful objective or symptomatic, and absent.
The disease was classified as regional where homolateral flap recurrence including lymph nodes, or contralateral breast and-nodes, or pleural effusion occurred. Skeletal, pulmonary metastases, visceral and distant skin metastases were classified as distant sites.
An analysis was made to ascertain any possible relationship between recorded data and response to drug therapy, including the effect on further response to endocrine ablation.
Administration of Drug
Initially cyclophosphamide was given intravenously on a thrice weekly basis; the usual intravenous dose was 300 mg with the exceptionof one small initial group in whom it was 400 mg. The mean dose intensity of the group showing objective response was 6,450 mg, or 136 mg per day. This corresponds roughly with the giving of 900 mg weekly and this lesser dose intensity was accepted. The patients showing no response received a total mean dose of 5,300 mg, a lower dose, because treatment was stopped when it Table 1 Response to cyclophosphamide of patients with breast cancer with involvement of regional or distant sites became obvious that no response was being obtained. Treatment continued until a total intravenous dose of 5-7 g of cyclophosphamide was given, occasionally more. Treatment was rested when WBC levels fell below 2,000 mm3. Platelet counts seemed less affected compared with white cell counts. Only one patient developed purpura and bone marrow recovery was rapid on stopping treatment. Where an objective improvement was obtained treatment was continued with oral therapy at 100-200 mg per day in the majority of cases.
Analysis of Treatment
The recorded responses for disease in each individual site are shown in Table 1 , the objective response rate by site being shown in the last column.
Disease contained within the homolateral or contralateral breast region, including nodes, responded in more instances than disease in other sites apart, perhaps, from distant skin nodules. The response for these regional sites is better in patients with regional disease only (53 % responding) than it is in those with general disease (390% responding). It may be that this is due to the widespread nature of the disease or some progressive factor of the disease itself, as discussed by Lyons (1963) .
In order to carry out further assessment it was decided to place patients into one of two main groups: (1) Those who showed a clear-cut objective response. (2) Those who showed an equivocal or no response.
The clear-cut objective response was defined by an obvious reduction in measured size of the lesion or radiographic improvement.
Cases showing symptomatic improvement only were included with the non-responders.
The time from first symptom to initial treatment, whether mastectomy, radiotherapy, or endocrine surgery, showed a similar distribution for both responders and non-responders. A similar distribution applies to the relationship between time from first symptom and cyclophosphamide (Table 2) . Table 3 shows that there is little difference between responders and non-responders as regards age group, interval between menopause and drug, interval between mastectomy and recurrence, or interval between first recurrence and the drug. The mean survival time for those patients showing an objective response is 13-4 months as against 9 3 months for those showing no response.
Leukopenia is often considered as a quantitative indicator of effective dose (Anders 1964) rather than an unwanted side-effect. However, no deliberate attempt was made by us to depress the white cell count to around 2,000/mm3.
The mean lowest white blood count for all cases was 3,147/mm3. Comparison of cases with a WBC above this figure and those with a WBC below it indicates that patients with regional disease only show a better chance of response to cyclophosphamide (Fig 1) .
The possibility of adrenal insufficiency in patients having cyclophosphamide has been suggested by Tipton (1965) . A comparison of response of patients with cancer of the breast to endocrine ablation before and after cyclophosphamide was made. Ablation in this case was either oophorectomy, adrenalectomy, or hypophysectomy. Some patients had more than one of these procedures. Of 46 patients treated with PATTERN OF SURVIVAL FOR REGIONAL SITES ONLY (Table 4) . Similarly, for patients treated with cyclophosphamide after endocrine ablation 24 out of 46 responded, the percentage difference not being significant. The administration of cyclophosphamide before ablative surgery, however, did appear to influence the response rate to the latter. Our results showed a poor response to ablative endocrine therapy, 3 out of 27 patients, of which 14 had shown previous response to cyclophosphamide. These results seem to confirm that cyclophosphamide does have a suppressant effect on the endocrine system.
Dividing patients into those under and over 55 years of age shows no particular trend, this age being chosen as being representative of the age at which all natural ovarian function should have stopped. The pattern of survival for patients with disease at regional sites only (Fig 2) shows that the objective effects of cyclophosphamide are maintained but the difference between the two groups becomes less as time proceeds. This seems to indicate that the effect of the drug is one of delay on the inevitable progress of the disease.
Quality ofLife It is, perhaps, too easy to think in terms of length of life without considering the quality of life and also the morbidity produced by having treatment. Although the treatment should not produce symptoms which are worse than the disease itself, provided those symptoms are acceptable to the patient, they may be considered a reasonable exchange for an increase in life. Table 5 shows the morbidity figures as a result of treatment. This indicates that approximately 10% of all patients develop some form of symptoms as a result of treatment. Alopecia of sufficient degree to be noticeable was present in 8 responders and 5 non-responders. Nine other patients developed symptoms which did not affect treatment except in the case which developed purpura.
As far as possible treatment was on an outpatient basis in order to minimize inconvenience to the patient. Blood counts were done twice weekly to begin with and then once weekly; finally once every two weeks while having oral therapy.
Conclusion
From our analysis of 133 cases of advanced breast cancer treated with cyclophosphamide, local disease of the breast areas and regional nodes responded objectively in some 45%. of cases, distant sites responding less dramatically. Most remissions were short lived but could be dramatic and prolonged. The longest response seen was over three years. The incidence of alopecia did not seem significantly related to response although higher in the responders. Regional response also appeared to occur to an increased extent in those patients whose white blood count was depressed below 3,000. However, there seems no reason, from our results, for deliberately giving higher doses of cyclophosphamide in order to depress the white blood count in the hope of an increased response. If this is done the morbidity effects would also rise and therefore affect the quality of life.
Finally, the administration of cyclophosphamide does appear to affect the chance of response to later endocrine surgery without itself offering a significantly increased chance of survival in these patients. ( Cell populations can be described in relation to their histological type and differentiation and in terms of their proliferative activity. The combined use of tritiated thymidine (3H-TdR) as a specific label for DNA synthesis and high resolution autoradiography to locate these cells and their progeny is the principal method in cell kinetic studies. The past fifteen years has seen this approach develop into a sophisticated and powerful analytical technique in biology. In broad terms, cells can be in one of three different functional states: engaged in cyclic division, the period between two mitoses being sub-divided into three, according to the condition of the DNA; G,, or the first gap, when the nucleus contains a metabolically stable post-mitotic amount of DNA (the diploid amount in normal somatic cells); S, a period of DNA replication; G2, or second gap, when the nucleus contains twice the post-mitotic DNA content, ready for the next cell division (the tetraploid amount in normal cells). Many cells differentiate and leave the proliferating compartment, lose their proliferative capacity, and eventually die, i.e. erythrocytes, polymorphonuclear leukocytes and cells in the skin or gut. A third possibility is for the cell to retain its potential for division but not to express this function until provided with an appropriate stimulus, the so-called Go state. Go cells are found in the stem cell compartments of the renewal tissues and probably occur in many tumour cell populations. Whatever the precise mechanism that enables the Go cell to remain out of cycle for long periods, it appears to give the cell an advantage when under attack from chemotherapeutic agents, as can be seen in studies of the properties of bone marrow stem cells (Harriss & Aponte 1968).
The cell kinetics of acute leukemia in man, and various model systems in animals, have been investigated in considerable detail. The present remarks are limited to acute leukemia, as the chronic leukemias present rather different problems.
Cronkite (1968) and Killmann (1968) have reviewed our knowledge of the proliferation of leukwmia in man and the following points appear to be highly relevant to understanding the target against which we are directing chemotherapy. The cell proliferation in untreated, acute
